2011
DOI: 10.2183/pjab.87.29
|View full text |Cite
|
Sign up to set email alerts
|

Structure-based development of specific inhibitors for individual cathepsins and their medical applications

Abstract: Specific inhibitors for individual cathepsins have been developed based on their tertiary structures of X-ray crystallography. Cathepsin B-specific inhibitors, CA-074 and CA-030, and cathepsin L specific inhibitors, CLIK-148 and CLIK-195, were designed as the epoxysuccinate derivatives. Cathepsin S inhibitor, CLIK-060, and cathepsin K inhibitor, CLIK-166, were synthesized. These inhibitors can use in vitro and also in vivo, and show no toxicity for experimental animals by the amounts used as the cathepsin inhi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
50
0

Year Published

2011
2011
2017
2017

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 50 publications
(53 citation statements)
references
References 26 publications
3
50
0
Order By: Relevance
“…9). Similar results were obtained with E-64, another cysteine protease inhibitor (32). These findings suggest that cathepsin B and other cathepsins contribute to the detachment of dead cells.…”
Section: Discussionsupporting
confidence: 84%
See 1 more Smart Citation
“…9). Similar results were obtained with E-64, another cysteine protease inhibitor (32). These findings suggest that cathepsin B and other cathepsins contribute to the detachment of dead cells.…”
Section: Discussionsupporting
confidence: 84%
“…It was difficult to investigate all the contributions of the many lysosome-hydrolyzing enzymes regarding streptococcal H 2 O 2 -mediated cell death; however, we investigated the possible contribution of cathepsin B using CA-074 Me, a specific cathepsin B inhibitor (32). Contrary to our expectations, the inhibitor did not inhibit cell death (Fig.…”
Section: Discussionmentioning
confidence: 62%
“…In the field of proteases, the move from bench to bedside encompasses a wide range of protease inhibitors that can be applied to treat various diseases, mostly with the aim to limit excessive proteolytic activities. Examples are hypertension (ACE inhibitors), diabetes (DPPIV inhibitors), AIDS (HIV protease inhibitors), and many more, while anti-cancer therapies have proved more difficult to achieve (Bromme and Lecaille 2009;Chen et al 2011;Coussens et al 2002;Demuth et al 2005;Huber and Groll 2012;Katunuma 2011;Li et al 2014;Stein and Groll 2014;Turk 2006). While clinical trials with inhibitors of MMPs were ill-defined and entered the clinical phase prematurely, the example of bortezomib as a proteasome inhibitor that blocks cellular protein turnover, and therefore acts in a much less specific manner, has been used successfully to treat certain tumors.…”
Section: The Protease Family Businessmentioning
confidence: 99%
“…By using this inhibitor as a frame and applying X-ray crystal structures of cathepsins B and L, specific inhibitors of these enzymes were designed (Fig. 3), prepared and shown to have promising anticancer activity in animal studies (Katunuma, 2011). Traditionally, secondary metabolites from streptomyces show a wide range of diversity with respect to their biological activity and chemical nature.…”
Section: Inhibitors From Natural Sourcesmentioning
confidence: 99%